Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 791-795

  Byrd, John C ^a   Waselenko, Jamie K ^a   Maneatis, Thomas J ^a   Murphy, Timothy ^a   Ward, Frank T ^a   Monahan, Brian P ^a   Sipe, Melissa A ^a   Donegan, Sarah ^a   White, Christine A ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; ASCITES; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG SAFETY; FEMALE; HUMAN; LUNG TOXICITY; LYMPHADENOPATHY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; THROMBOCYTOPENIA;

EID: 0033016566     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.791     Document Type: Article

References (12)

1. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
2. Reff ME, Carner K, Chambers S, et al: Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
3. Maloney DJ, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (rituximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997 (abstr 349)
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
5. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
6. Piro L, White CA, Grillo-Lopez AJ, et al: Rituxan: Interim analysis of a phase II study of once weekly times eight dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma. Blood 90:510, 1997 (abstr 2272)
7. Cheson BD, Frame JN, Vena D, et al: Tumor lysis syndrome: An uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 16:2313-2320, 1998
8. Cohen LF, Balow JE, Magrath IT, et al: Acute tumor lysis syndrome: A review of 37 patients with Burkitt's lymphoma. Am J Med 68:486-491, 1980
9. Stapleton FB, Strother DR, Roy S, et al: Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B-cell acute lymphoblastic lymphoma. Pediatrics 82:863-869, 1988
10. Hande K, Garrow GC: Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 94:133-139, 1993
11. Wing MG, Moreau T, Greenwood J, et al: Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcgammaRIII) and CD 11a/CD18 (LFA-1) on NK cells. J Clin Invest 98:2819-2826, 1996
12. Moreau T, Coles A, Wing MG, et al: Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119:225-237, 1996